Aspire Biopharma Registers 147M Shares for Resale, Seeks Reverse Split Nod

Ticker: ASBPW · Form: S-1 · Filed: Sep 18, 2025 · CIK: 1847345

Sentiment: bearish

Topics: Biopharma, S-1 Filing, Convertible Notes, Share Dilution, Reverse Stock Split, Nasdaq Listing, Penny Stock

Related Tickers: ASBP, ASBPW

TL;DR

**Aspire Biopharma's S-1 screams dilution and desperation, making ASBPW a high-risk bet with a looming reverse split and massive share overhang.**

AI Summary

Aspire Biopharma Holdings, Inc. (ASBPW) filed an S-1 on September 18, 2025, to register the resale of up to 147,177,424 shares of common stock underlying Convertible Promissory Notes. These Notes, with an aggregate principal amount of $9,687,500 and a 20% original issue discount, were issued on August 19, 2025, under a Securities Purchase Agreement for a subscription price of $7,750,000. The company received $4,709,677 in the first tranche, with an additional $1,000,000 expected after filing and $2,250,000 upon the S-1's effectiveness. As of September 17, 2025, the outstanding balance of the Notes was $5,887,097, convertible into up to 73,588,712 shares at a floor price of $0.0839 per share, subject to a 4.99% beneficial ownership blocker. Aspire will not receive proceeds from the resale of these conversion shares but will bear registration costs. The company is seeking shareholder approval by November 4, 2025, for the issuance of over 19.99% of outstanding shares and a potential reverse stock split between one-for-five and one-for-forty.

Why It Matters

This S-1 filing signals a significant dilution risk for existing ASBPW investors, as up to 147,177,424 shares could enter the market from the conversion of promissory notes, potentially depressing the stock price from its September 17, 2025, closing of $0.45 per share. The company's reliance on convertible debt for funding, with a 20% original issue discount, highlights ongoing financial challenges and a need for capital. Furthermore, the proposed reverse stock split, ranging from one-for-five to one-for-forty, indicates a struggle to maintain Nasdaq listing standards and could further impact investor confidence, especially given the current low share price. Competitors in the biopharma space with stronger balance sheets and less dilutive financing structures may gain an advantage.

Risk Assessment

Risk Level: high — The S-1 explicitly states the registration of up to 147,177,424 shares for resale, representing a substantial potential dilution to existing shareholders, especially given the September 17, 2025, closing price of $0.45 per share. The company also disclosed a need for shareholder approval for the issuance of more than 19.99% of outstanding shares and a potential reverse stock split between one-for-five and one-for-forty, indicating significant financial distress and a risk of delisting from Nasdaq.

Analyst Insight

Investors should exercise extreme caution and consider avoiding ASBPW given the imminent and substantial dilution from the 147,177,424 shares underlying convertible notes. The proposed reverse stock split, a common tactic for companies facing delisting, signals severe underlying issues; investors should wait for clarity on the company's long-term viability and financial stability before considering any position.

Financial Highlights

debt To Equity
Not Disclosed
revenue
$0
operating Margin
Not Disclosed
total Assets
Not Disclosed
total Debt
$5.89M
net Income
Not Disclosed
eps
Not Disclosed
gross Margin
Not Disclosed
cash Position
Not Disclosed
revenue Growth
N/A

Key Numbers

Key Players & Entities

FAQ

What is Aspire Biopharma Holdings, Inc. registering in its S-1 filing?

Aspire Biopharma Holdings, Inc. is registering the resale of up to 147,177,424 shares of common stock. These shares are issuable upon the conversion of Convertible Promissory Notes with an aggregate principal amount of $9,687,500.

How much funding did Aspire Biopharma receive from the Convertible Promissory Notes?

Aspire Biopharma received $4,709,677 in the first tranche on August 19, 2025. An additional $1,000,000 is expected after the S-1 filing, and $2,250,000 upon the effectiveness of the Registration Statement, totaling a subscription price of $7,750,000.

What is the conversion price for the Convertible Promissory Notes?

The conversion price for the Notes is the greater of (i) 80% of the lowest closing price during the five trading days prior to conversion or (ii) a floor price of $0.0839 per share, which is 20% of the average closing price for five days prior to the closing date.

Will Aspire Biopharma receive any proceeds from the sale of these registered securities?

No, Aspire Biopharma Holdings, Inc. will not receive any proceeds from the sale of the Conversion Shares by the Selling Shareholders. The company will, however, bear all costs, expenses, and fees associated with the registration.

What shareholder approvals is Aspire Biopharma seeking?

Aspire Biopharma is seeking shareholder approval for the issuance of more than 19.99% of its outstanding common stock upon conversion of the Notes and for the floor price. Additionally, it seeks approval for a reverse stock split between one-for-five and one-for-forty.

When is the special meeting for shareholder approvals scheduled?

The Company intends to hold a special meeting of stockholders on November 4, 2025, at 10:00 A.M. Eastern Time, in person at 4626 N 300 W, Suite 350, Provo, UT 84604, to solicit votes for these proposals.

What was the closing price of Aspire Biopharma's common stock on September 17, 2025?

On September 17, 2025, the closing sale price of Aspire Biopharma's common stock (ASBP) as reported by Nasdaq was $0.45 per share, and its warrants (ASBPW) closed at $0.0362 per warrant.

What is the 'Note Blocker' mentioned in the S-1 filing?

The 'Note Blocker' prevents a purchaser from converting Notes if, after conversion, they would beneficially own in excess of 4.99% of Aspire's outstanding common stock. This limit can be raised or lowered to any percentage not exceeding 9.99% with 61-days' prior notice.

What are the risks associated with investing in Aspire Biopharma, according to the S-1?

Key risks include a history of operating losses, difficulties managing growth, dependence on skilled personnel, inadequate intellectual property protection, volatile stock price, and identified material weaknesses in internal control over financial reporting. The potential for significant dilution from the registered shares is also a major risk.

What is the maturity date of the Convertible Promissory Notes?

The Convertible Promissory Notes issued by Aspire Biopharma Holdings, Inc. have a maturity date of February 19, 2026.

Risk Factors

Industry Context

Aspire Biopharma operates in the biopharmaceutical industry, a sector characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. The market is competitive, with many companies vying for drug approvals and market share. Trends include advancements in drug delivery technologies, personalized medicine, and increasing reliance on contract manufacturing organizations (CMOs) for production.

Regulatory Implications

The company faces significant regulatory risks related to FDA approval processes for its drug candidates. Failure to obtain or maintain FDA approval for its products would severely impact its ability to generate revenue. Compliance with cGMP standards by its contract manufacturers is also a critical regulatory requirement.

What Investors Should Do

  1. Monitor Shareholder Vote Outcome
  2. Assess Dilution Impact
  3. Track Funding Milestones
  4. Evaluate Commercialization Strategy

Key Dates

Glossary

Convertible Promissory Notes
Debt instruments that can be converted into a predetermined amount of equity (common stock) at the holder's option. (These notes represent a significant portion of the company's capital structure and are a source of potential future share dilution.)
Original Issue Discount (OID)
The difference between the face value of a debt instrument and the price at which it is sold, when the selling price is less than the face value. (The 20% OID on the notes means the company received less cash than the principal amount, increasing the effective cost of this debt.)
Beneficial Ownership Blocker
A provision in a convertible security that limits the number of shares a holder can convert into if doing so would cause them to exceed a specified ownership percentage (e.g., 4.99%). (This prevents immediate, large-scale conversion that could drastically alter the company's ownership structure and stock price.)
Reverse Stock Split
A corporate action where a company reduces the total number of its outstanding shares by consolidating existing shares into fewer, proportionally more valuable shares. (Aspire Biopharma is considering this to potentially increase its stock price to meet exchange listing requirements.)
S-1 Filing
A registration statement filed with the U.S. Securities and Exchange Commission (SEC) by companies planning to offer securities to the public. (This filing allows for the resale of shares underlying the convertible notes, making them available to the public market.)
cGMP
Current Good Manufacturing Practice. Regulations enforced by the FDA to ensure that products are consistently produced and controlled according to quality standards. (Compliance is critical for the company's contract manufacturers to ensure product quality and regulatory approval.)

Year-Over-Year Comparison

This S-1 filing is for the resale of shares underlying convertible notes, indicating a shift from a primary offering to facilitating liquidity for noteholders. Unlike a typical IPO or follow-on offering, Aspire Biopharma will not receive proceeds from this resale. The filing also highlights the company's ongoing need for capital, evidenced by the outstanding convertible note balance and the planned reverse stock split, suggesting a challenging financial position compared to previous periods.

Filing Stats: 4,557 words · 18 min read · ~15 pages · Grade level 16.5 · Accepted 2025-09-18 16:56:43

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 42 DETERMINATION OF OFFERING PRICE 42 DIVIDEND POLICY 43 MARKET INFORMATION 43

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 43

BUSINESS

BUSINESS 51 Management 59 Executive and Director Compensation 66 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 75 PRINCIPAL STOCKHOLDERS 78 Selling Shareholders 79

Description of Capital Stock

Description of Capital Stock 81 SECURITIES ACT RESTRICTIONS ON RESALE OF COMMON STOCK 83 PLAN OF DISTRIBUTION (CONFLICT OF INTEREST) 84 LEGAL MATTERS 86 EXPERTS 86 Where You Can Find More Information 86 INDEX TO CONSOLIDATED FINANCIAL STATEMENTS F-1 i ABOUT THIS PROSPECTUS You should rely only on the information contained in this prospectus or in any applicable prospectus supplement prepared by us or on our behalf. Neither we nor the Selling Shareholders have authorized anyone to provide any information or to make any representations other than those contained in this prospectus, any accompanying prospectus supplement or any free writing prospectus we have prepared. We and the Selling Shareholders take no responsibility for, and can provide no assurance as to the reliability of, any other information that others may give you. This prospectus is an offer to sell only the securities offered hereby and only under circumstances and in jurisdictions where it is lawful to do so. No dealer, salesperson or other person is authorized to give any information or to represent anything not contained in this prospectus, any applicable prospectus supplement or any related free writing prospectus. This prospectus is not an offer to sell securities, and it is not soliciting an offer to buy securities, in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or any prospectus supplement is accurate only as of the date on the front of those documents only, regardless of the time of delivery of this prospectus or any applicable prospectus supplement, or any sale of a security. Our business, financial condition, results of operations and prospects may have changed since those dates. This prospectus is part of a registration statement on Form S-1 that we filed with the SEC using the "shelf" registration process. Under this shelf registration process, the Selling Shareholders hereund

forward-looking statements

forward-looking statements. The following summarizes the risks and uncertainties that could materially adversely affect our business, financial condition, results of operation and stock price. You should read this summary together with the more detailed description of each risk factor contained below. Unless the context otherwise requires, all references in this subsection to the "Company," "we," "us," or "our" refer to the business of Aspire. We have a history of operating losses and there is no assurance that we will ever be able to earn sufficient revenue to achieve profitability or raise additional financing to successfully operate our business plan. We will need to increase the size of our organization, and we may experience difficulties in managing growth, which could hurt our financial performance. Our business depends on experienced and skilled personnel, and if we are unable to attract and integrate skilled personnel, it will be more difficult for us to manage our business and complete contracts. If we do not adequately protect our intellectual property rights, we may experience a loss of revenue and our operations and growth prospects may be materially harmed. The market price of our common stock may be volatile and fluctuate substantially, which could cause the value of your investment to decline. Changes in accounting principles and guidance, or their interpretation or implementation, may materially adversely affect our reported results of operations or financial position. If we fail to meet the continued listing standards of Nasdaq, our common stock may be delisted, which could have a material adverse effect on the liquidity and market price of our common stock and expose us to litigation. Management has identified material weaknesses in our internal control over financial reporting, which could, if not remediated, result in additional material misstatements in our interim or annual consolidated financial statements. Should one or mo

Business

Business Plan We expect to generate revenue through developing and marketing drugs and nutraceuticals using the technology for the novel sublingual delivery. Further, from time to time, we may enter into license or collaboration agreements with other companies that include development funding and significant upfront and milestone payments and/or royalties, which may become an important source of our revenue. Accordingly, our revenue may depend on development funding and the achievement of development and clinical milestones under current and any potential future license and collaboration agreements and sales of our products, if approved. We do not currently have any licensing or collaboration agreements. Manufacturing We currently contract with third parties for the manufacture of our product candidates for preclinical studies, clinical trials, and sale, and intend to do so in the future. We do not own or operate manufacturing facilities for the production of clinical or commercial quantities of our product candidates. We currently have no plans to build our own clinical or commercial scale manufacturing capabilities. To meet our projected needs for commercial manufacturing, third parties with whom we currently work will need to increase their scale of production or we will need to secure alternate suppliers. Although we rely on contract manufacturers, we have personnel with manufacturing experience to oversee our relationships with contract manufacturers. We entered into a development and manufacturing agreement with a contract manufacturer, Glatt, in the fourth quarter of 2024, under which Glatt produced sufficient quantities of our high-dose sublingual aspirin product (sometimes referred to informally herein as "Instaprin" for ease of reference) for our clinical trials required to obtain FDA approval to market the product and complete clinical trials. While we believe that Glatt is capable of producing the drug product to support our aspirin product devel

View Full Filing

View this S-1 filing on SEC EDGAR

View on Read The Filing